Shaperon KRX:378800KOSDAQ
샤페론 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days8
DART filings, 7 days2
Articles tracked15since Sep 11
In Q2 2026, Shaperon reported revenue of ₩41m and an operating loss of ₩3.1bn. Shaperon (샤페론) appeared in 8 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Sep 22 with 7 articles. The most common catalyst was contracts & orders (3). It was most often mentioned alongside Cellid and SCL Science.
Filing signals Clinical trial filing 4 quarters of losses Screener
Shaperon quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩41m | – | −₩3.1bn | −₩3.7bn |
| Q1 2026 | ₩65m | +454.1% | −₩3.7bn | −₩3.5bn |
| Q4 2025 derived | ₩48m | – | −₩4.4bn | −₩4.4bn |
| Q3 2025 | ₩168m | – | −₩4.4bn | −₩4.2bn |
| Q2 2025 | ₩0m | -100.0% | −₩3.4bn | −₩3.4bn |
| Q1 2025 | ₩12m | – | −₩3.6bn | −₩3.5bn |
| Q4 2024 derived | ₩0m | -100.0% | −₩3.5bn | −₩3.4bn |
| Q3 2024 | ₩0m | – | −₩3.1bn | −₩2.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Shaperon top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Shaperon news Korean headlines
-
샤페론, 차세대 NDC 플랫폼 공개…PdRaxane 전임상서 종양 억제 효과 확인
1 more on this story · 1 outlets
- 샤페론, 차세대 NDC 플랫폼 공개...6분의 1 용량으로 종양 억제·생존 개선 효과 확인팍스경제TV · Sep 22 17:27